MEDINDIA
English
हिन्दी
Español
français
中文
Email
Acebutolol
Acebutolol may increase the vasoconstricting activities of Methylergometrine.
Acetaminophen
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Acetaminophen.
Acetazolamide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Acetazolamide.
Adrafinil
Methylergometrine may increase the hypertensive and vasoconstricting activities of Adrafinil.
Albuterol
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Salbutamol.
Aldesleukin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Aldesleukin.
Almotriptan
Methylergometrine may increase the vasoconstricting activities of Almotriptan.
Alogliptin
The serum concentration of Methylergometrine can be increased when it is combined with Alogliptin.
alpha 1-Antitrypsin
The serum concentration of Methylergometrine can be increased when it is combined with Alpha-1-proteinase inhibitor.
Alpha 1-Proteinase Inhibitor, Human
The serum concentration of Methylergometrine can be increased when it is combined with Alpha-1-proteinase inhibitor.
Alprazolam
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Alprazolam.
Alprenolol
Alprenolol may increase the vasoconstricting activities of Methylergometrine.
Ambroxol
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ambroxol.
Amlodipine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Amlodipine.
Amprenavir
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Amprenavir.
Anastrozole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Anastrozole.
Anhydrous Tacrolimus
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tacrolimus.
Antipyrine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Antipyrine.
Antithrombin III
The serum concentration of Methylergometrine can be increased when it is combined with Antithrombin III human.
Antithrombin III, Human
The serum concentration of Methylergometrine can be increased when it is combined with Antithrombin III human.
Apixaban
The serum concentration of Methylergometrine can be increased when it is combined with Apixaban.
Apomorphine
Methylergometrine may increase the vasoconstricting activities of Apomorphine.
Apraclonidine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Apraclonidine.
Aprotinin
The serum concentration of Methylergometrine can be increased when it is combined with Aprotinin.
Arbutamine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Arbutamine.
Arformoterol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Arformoterol.
Argatroban
The serum concentration of Methylergometrine can be increased when it is combined with Argatroban.
Argatroban Anhydrous
The serum concentration of Methylergometrine can be increased when it is combined with Argatroban.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Arsenic trioxide.
Astemizole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Astemizole.
Asunaprevir
The serum concentration of Methylergometrine can be increased when it is combined with Asunaprevir.
Atazanavir
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Atazanavir.
Atenolol
Atenolol may increase the vasoconstricting activities of Methylergometrine.
Atomoxetine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Atomoxetine.
Atorvastatin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Atorvastatin.
Azelastine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Azelastine.
Azithromycin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Azithromycin.
Benazepril
The serum concentration of Methylergometrine can be increased when it is combined with Benazepril.
Betamethasone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Betamethasone.
Betaxolol
Betaxolol may increase the vasoconstricting activities of Methylergometrine.
Bicalutamide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Bicalutamide.
Bifonazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Bifonazole.
Bisoprolol
Bisoprolol may increase the vasoconstricting activities of Methylergometrine.
Bitolterol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Bitolterol.
Bitolterol Mesylate
Methylergometrine may increase the hypertensive and vasoconstricting activities of Bitolterol.
Bivalirudin
The serum concentration of Methylergometrine can be increased when it is combined with Bivalirudin.
Boceprevir
The serum concentration of Methylergometrine can be increased when it is combined with Boceprevir.
Bopindolol
Bopindolol may increase the vasoconstricting activities of Methylergometrine.
Bortezomib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Bortezomib.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Methylergometrine.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Methylergometrine.
Brentuximab Vedotin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Brentuximab vedotin.
Brimonidine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Brimonidine.
Bromocriptine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Bromocriptine.
Bupranolol
Bupranolol may increase the vasoconstricting activities of Methylergometrine.
Buprenorphine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Buprenorphine.
Cabergoline
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Cabergoline.
Caffeine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Caffeine.
Capsaicin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Capsaicin.
Captopril
The serum concentration of Methylergometrine can be increased when it is combined with Captopril.
Carboprost
The risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Methylergometrine.
Carboprost Tromethamine
The risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Methylergometrine.
Carteolol
Carteolol may increase the vasoconstricting activities of Methylergometrine.
Carvedilol
Carvedilol may increase the vasoconstricting activities of Methylergometrine.
Caspofungin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Caspofungin.
Celiprolol
Celiprolol may increase the vasoconstricting activities of Methylergometrine.
Ceritinib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Methylergometrine.
Chloramphenicol
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Chloramphenicol.
Chlorzoxazone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Chlorzoxazone.
Cholesterol
The serum concentration of Methylergometrine can be increased when it is combined with Cholesterol.
Cilastatin
The serum concentration of Methylergometrine can be increased when it is combined with Cilastatin.
Cilazapril
The serum concentration of Methylergometrine can be increased when it is combined with Cilazapril.
Cilostazol
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Cilostazol.
Ciprofloxacin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ciprofloxacin.
Cisapride
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Cisapride.
Clarithromycin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Clarithromycin.
Clemastine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Clemastine.
Clenbuterol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Clenbuterol.
Clindamycin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Clindamycin.
Clofazimine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Clofazimine.
Clofezone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Rabeprazole.
Clomiphene
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Clomifene.
Clonidine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Clonidine.
Clotiazepam
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Clotiazepam.
Clotrimazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Clotrimazole.
Clozapine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Clozapine.
Cobicistat
The serum concentration of Methylergometrine can be increased when it is combined with Cobicistat.
Cocaine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Cocaine.
Colchicine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Colchicine.
Conivaptan
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Conivaptan.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Cortisone acetate.
Crizotinib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Crizotinib.
Cyclophosphamide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Cyclophosphamide.
Cyclophosphamide Anhydrous
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Cyclophosphamide.
Cyclosporine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Cyclosporine.
Dabigatran Etexilate
The serum concentration of Methylergometrine can be increased when it is combined with Dabigatran etexilate.
Dalfopristin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Dalfopristin.
Danazol
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Danazol.
Darunavir
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Darunavir.
Dasatinib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Dasatinib.
Dasatinib Anhydrous
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Dasatinib.
Daunorubicin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Daunorubicin.
Delavirdine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Delavirdine.
Desipramine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Desipramine.
Dexamethasone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Dexamethasone.
Dexmedetomidine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Dexmedetomidine.
Diazepam
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Diazepam.
Diethylstilbestrol
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Diethylstilbestrol.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methylergometrine.
Dimethyl Sulfoxide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Dimethyl sulfoxide.
Dipivefrin
Methylergometrine may increase the hypertensive and vasoconstricting activities of Dipivefrin.
Dobutamine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Dobutamine.
Docetaxel
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Docetaxel.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Docetaxel.
Dopexamine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Dopexamine.
Doxorubicin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Doxorubicin.
Doxorubicin Hydrochloride
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Doxorubicin.
Doxycycline
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Doxycycline.
Doxycycline Anhydrous
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Doxycycline.
Dronedarone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Dronedarone.
Droxidopa
Methylergometrine may increase the hypertensive and vasoconstricting activities of Droxidopa.
Econazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Econazole.
Econazole Nitrate
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Econazole.
Edoxaban
The serum concentration of Methylergometrine can be increased when it is combined with Edoxaban.
Efavirenz
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Efavirenz.
Elbasvir
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Elbasvir.
Eletriptan
Methylergometrine may increase the vasoconstricting activities of Eletriptan.
Enalapril
The serum concentration of Methylergometrine can be increased when it is combined with Enalapril.
Enalaprilat
The serum concentration of Methylergometrine can be increased when it is combined with Enalaprilat.
Enalaprilat Anhydrous
The serum concentration of Methylergometrine can be increased when it is combined with Enalaprilat.
Enasidenib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Enasidenib.
Ephedrine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Ephedrine.
Epigallocatechin Gallate
The serum concentration of Methylergometrine can be increased when it is combined with Epigallocatechin Gallate.
Epinastine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Epinastine.
Epinephrine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Epinephrine.
ergoloid mesylates, USP
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ergoloid mesylate.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Methylergometrine.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Methylergometrine.
Erythromycin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Erythromycin.
Esmolol
Esmolol may increase the vasoconstricting activities of Methylergometrine.
Ethanol
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ethanol.
Etilefrine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Etilefrine.
Etoposide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Etoposide.
Etoricoxib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Etoricoxib.
Ezetimibe
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ezetimibe.
Felodipine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Felodipine.
Fenoterol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Fenoterol.
Fentanyl
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Fentanyl.
Fibrinolysis Inhibitor
The serum concentration of Methylergometrine can be increased when it is combined with Aprotinin.
Fluoxetine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Fluoxetine.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Fluticasone propionate.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Methylergometrine.
Fluvoxamine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Fluvoxamine.
Formoterol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Formoterol.
Fosamprenavir
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Fosamprenavir.
Fosaprepitant
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Fosaprepitant.
Fosinopril
The serum concentration of Methylergometrine can be increased when it is combined with Fosinopril.
Frovatriptan
Methylergometrine may increase the vasoconstricting activities of Frovatriptan.
Gemfibrozil
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Gemfibrozil.
Glyburide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Glyburide.
Glycerol Phenylbutyrate
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Glycerol Phenylbutyrate.
Guanabenz
Methylergometrine may increase the hypertensive and vasoconstricting activities of Guanabenz.
Guanfacine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Guanfacine.
Haloperidol
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Haloperidol.
Hexoprenaline
Methylergometrine may increase the hypertensive and vasoconstricting activities of Hexoprenaline.
Histamine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Histamine.
Hydralazine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Hydralazine.
Hydrocortisone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Hydrocortisone.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Methylergometrine.
Idelalisib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Idelalisib.
Ifosfamide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ifosfamide.
Iloperidone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Iloperidone.
Imatinib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Imatinib.
Imidapril
The serum concentration of Methylergometrine can be increased when it is combined with Imidapril.
Indinavir
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Indinavir.
INDINAVIR ANHYDROUS
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Indinavir.
Irbesartan
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Irbesartan.
Irinotecan
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Irinotecan.
Isavuconazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Isavuconazole.
Isavuconazonium
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Isavuconazonium.
Isoetharine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Isoetarine.
Isoflurophate
The serum concentration of Methylergometrine can be increased when it is combined with Isoflurophate.
Isoniazid
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Isoniazid.
Isoproterenol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Isoprenaline.
Isoxsuprine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Isoxsuprine.
Isradipine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Isradipine.
Itraconazole
The serum concentration of Methylergometrine can be increased when it is combined with Itraconazole.
Ivacaftor
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ivacaftor.
Ixazomib
The serum concentration of Methylergometrine can be increased when it is combined with Ixazomib.
Josamycin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Josamycin.
Ketazolam
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ketazolam.
Ketoconazole
The serum concentration of Methylergometrine can be increased when it is combined with Ketoconazole.
Labetalol
Labetalol may increase the vasoconstricting activities of Methylergometrine.
Lansoprazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lansoprazole.
Lapatinib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lapatinib.
Lepirudin
The serum concentration of Methylergometrine can be increased when it is combined with Lepirudin.
Lercanidipine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lercanidipine.
Levalbuterol
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Levosalbutamol.
Levobunolol
Levobunolol may increase the vasoconstricting activities of Methylergometrine.
Levofloxacin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Levofloxacin.
Levofloxacin Anhydrous
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Levofloxacin.
Lidocaine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lidocaine.
Linagliptin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Linagliptin.
Lisinopril
The serum concentration of Methylergometrine can be increased when it is combined with Lisinopril.
Lisinopril Anhydrous
The serum concentration of Methylergometrine can be increased when it is combined with Lisinopril.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Methylergometrine.
Lofexidine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Lofexidine.
Lomitapide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lomitapide.
Lomustine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lomustine.
Lopinavir
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lopinavir.
Loratadine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Loratadine.
Lorcaserin
The risk or severity of adverse effects can be increased when Lorcaserin is combined with Methylergometrine.
Losartan
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Losartan.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Methylergometrine.
Luliconazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Luliconazole.
Lurasidone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lurasidone.
Manidipine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Manidipine.
Mefloquine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Mefloquine.
Mephentermine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Mephentermine.
Mequitazine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Mequitazine.
Metaproterenol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Orciprenaline.
Metaraminol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Metaraminol.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Methylergometrine.
Methadone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Methadone.
Methazolamide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Methazolamide.
Methimazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Methimazole.
Methoxamine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Methoxamine.
Methyldopa
Methylergometrine may increase the hypertensive and vasoconstricting activities of Methyldopa.
METHYLDOPA ANHYDROUS
Methylergometrine may increase the hypertensive and vasoconstricting activities of Methyldopa.
Methylprednisolone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Methylprednisolone.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Methylergometrine.
Metipranolol
Metipranolol may increase the vasoconstricting activities of Methylergometrine.
Metoprolol
Metoprolol may increase the vasoconstricting activities of Methylergometrine.
Metronidazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Metronidazole.
Metyrapone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Metyrapone.
Mibefradil
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Mibefradil.
Miconazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Miconazole.
Midazolam
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Midazolam.
Midodrine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Midodrine.
Mifepristone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Mifepristone.
Mirabegron
Methylergometrine may increase the hypertensive and vasoconstricting activities of Mirabegron.
Mirtazapine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Mirtazapine.
Mitoxantrone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Mitoxantrone.
Modafinil
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Modafinil.
Moexipril
The serum concentration of Methylergometrine can be increased when it is combined with Moexipril.
Nadolol
Nadolol may increase the vasoconstricting activities of Methylergometrine.
Naphazoline
Methylergometrine may increase the hypertensive and vasoconstricting activities of Naphazoline.
Naratriptan
Methylergometrine may increase the vasoconstricting activities of Naratriptan.
Nebivolol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Nebivolol.
Nelfinavir
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nelfinavir.
Netupitant
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Netupitant.
Nevirapine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nevirapine.
Niacinamide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nicotinamide.
Nicardipine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nicardipine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Methylergometrine.
Nifedipine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nifedipine.
Nilotinib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nilotinib.
Nilvadipine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nilvadipine.
Nisoldipine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nisoldipine.
Nitrendipine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nitrendipine.
Nitric Oxide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nitric Oxide.
Nitroglycerin
The bioavailability of Methylergometrine can be increased when combined with Nitroglycerin.
Norepinephrine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Norepinephrine.
Norfloxacin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Norfloxacin.
Noscapine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Noscapine.
Nylidrin
Methylergometrine may increase the hypertensive and vasoconstricting activities of Nylidrin.
O-PHENANTHROLINE
The serum concentration of Methylergometrine can be increased when it is combined with 1,10-Phenanthroline.
Olanzapine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Olanzapine.
Olaparib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Olaparib.
Olodaterol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Olodaterol.
Omeprazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Omeprazole.
Oxprenolol
Oxprenolol may increase the vasoconstricting activities of Methylergometrine.
Oxybutynin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Oxybutynin.
Oxymetazoline
Methylergometrine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.
Oxymetholone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Oxymetholone.
Paclitaxel
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Paclitaxel.
Palbociclib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Palbociclib.
Paramethasone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Paramethasone.
Pazopanib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Pazopanib.
Penbutolol
Penbutolol may increase the vasoconstricting activities of Methylergometrine.
Pergolide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Pergolide.
Perindopril
The serum concentration of Methylergometrine can be increased when it is combined with Perindopril.
Phenelzine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Phenelzine.
Phenylephrine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Phenylephrine.
Phenylpropanolamine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Phenylpropanolamine.
Pilocarpine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Pilocarpine.
Pimozide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Pimozide.
Pindolol
Pindolol may increase the vasoconstricting activities of Methylergometrine.
Pirbuterol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Pirbuterol.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Methylergometrine.
Posaconazole
The serum concentration of Methylergometrine can be increased when it is combined with Posaconazole.
Practolol
Practolol may increase the vasoconstricting activities of Methylergometrine.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Methylergometrine.
Prednisolone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Prednisone.
Primaquine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Primaquine.
Procaterol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Procaterol.
Progesterone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Progesterone.
Propofol
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Propofol.
Propoxyphene
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Dextropropoxyphene.
Propranolol
Propranolol may increase the vasoconstricting activities of Methylergometrine.
Pseudoephedrine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.
Quinapril
The serum concentration of Methylergometrine can be increased when it is combined with Quinapril.
Quinidine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Quinidine.
Quinine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Quinine.
Quinupristin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Quinupristin.
Rabeprazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Rabeprazole.
Racecadotril
The serum concentration of Methylergometrine can be increased when it is combined with Racecadotril.
Racepinephrine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Racepinephrine.
Raloxifene
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Raloxifene.
Ramipril
The serum concentration of Methylergometrine can be increased when it is combined with Ramipril.
Ranitidine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ranitidine.
Ranolazine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ranolazine.
Regorafenib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Regorafenib.
Repaglinide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Repaglinide.
Reproterol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Reproterol.
Resveratrol
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Resveratrol.
Rilmenidine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Rilmenidine.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Methylergometrine.
Risperidone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Risperidone.
Ritodrine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Ritodrine.
Ritonavir
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ritonavir.
Rivaroxaban
The serum concentration of Methylergometrine can be increased when it is combined with Rivaroxaban.
Rivastigmine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Rivastigmine.
Rizatriptan
Methylergometrine may increase the vasoconstricting activities of Rizatriptan.
Rolitetracycline
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Rolitetracycline.
Ropinirole
Methylergometrine may increase the vasoconstricting activities of Ropinirole.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Methylergometrine.
Roxithromycin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Roxithromycin.
Rucaparib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Rucaparib.
Rutin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Rutin.
Salmeterol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Salmeterol.
Saquinavir
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Saquinavir.
Saquinavir Mesylate
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Saquinavir.
Sarilumab
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Sarilumab.
Saxagliptin
The serum concentration of Methylergometrine can be increased when it is combined with Saxagliptin.
Saxagliptin Anhydrous
The serum concentration of Methylergometrine can be increased when it is combined with Saxagliptin.
Sertraline
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Sertraline.
Sildenafil
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Sildenafil.
Simeprevir
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Simeprevir.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Methylergometrine.
Sirolimus
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Sirolimus.
Sitagliptin
The serum concentration of Methylergometrine can be increased when it is combined with Sitagliptin.
Sitagliptin Phosphate
The serum concentration of Methylergometrine can be increased when it is combined with Sitagliptin.
Sorafenib
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Sorafenib.
Sotalol
Sotalol may increase the vasoconstricting activities of Methylergometrine.
Spirapril
The serum concentration of Methylergometrine can be increased when it is combined with Spirapril.
Sulfamethoxazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Sulfamethoxazole.
Sulfanilamide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Sulfanilamide.
Sulfinpyrazone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Sulfinpyrazone.
Sulfisoxazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Sulfisoxazole.
Sumatriptan
Methylergometrine may increase the vasoconstricting activities of Sumatriptan.
Sumatriptan Succinate
Methylergometrine may increase the vasoconstricting activities of Sumatriptan.
Synephrine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Synephrine.
Tacrolimus
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tacrolimus.
Tadalafil
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tadalafil.
Talinolol
Talinolol may increase the vasoconstricting activities of Methylergometrine.
Tamoxifen
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tamoxifen.
Telaprevir
The serum concentration of Methylergometrine can be increased when it is combined with Telaprevir.
Telithromycin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Telithromycin.
Temsirolimus
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Temsirolimus.
Teniposide
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Teniposide.
Terbutaline
Methylergometrine may increase the hypertensive and vasoconstricting activities of Terbutaline.
Terbutaline Sulfate
Methylergometrine may increase the hypertensive and vasoconstricting activities of Terbutaline.
Terfenadine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Terfenadine.
Testosterone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Testosterone.
Testosterone Cypionate
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Testosterone cypionate.
Testosterone Enanthate
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Testosterone enanthate.
Testosterone Undecanoate
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Testosterone undecanoate.
Tetracycline
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tetracycline.
Thiopental
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Thiopental.
Thiopental Sodium
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Thiopental.
Ticagrelor
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ticagrelor.
Ticlopidine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ticlopidine.
Timolol
Timolol may increase the vasoconstricting activities of Methylergometrine.
Timolol Anhydrous
Timolol may increase the vasoconstricting activities of Methylergometrine.
Tioconazole
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tioconazole.
Tipranavir
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tipranavir.
Tizanidine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Tizanidine.
Tofisopam
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tofisopam.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Methylergometrine.
Topotecan
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Topotecan.
Tramadol
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tramadol.
Trandolapril
The serum concentration of Methylergometrine can be increased when it is combined with Trandolapril.
Tranylcypromine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tranylcypromine.
Troglitazone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Troglitazone.
Troleandomycin
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Troleandomycin.
Tulobuterol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Tulobuterol.
Valproate
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Valproic Acid.
Valproic Acid
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Valproic Acid.
Venlafaxine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Venlafaxine.
Vilazodone
Methylergometrine may increase the vasoconstricting activities of Vilazodone.
Vildagliptin
The serum concentration of Methylergometrine can be increased when it is combined with Vildagliptin.
Vinblastine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Vinblastine.
Vincristine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Vincristine.
Vinorelbine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Vinorelbine.
Voriconazole
The serum concentration of Methylergometrine can be increased when it is combined with Voriconazole.
Vortioxetine
Methylergometrine may increase the vasoconstricting activities of Vortioxetine.
Xamoterol
Methylergometrine may increase the hypertensive and vasoconstricting activities of Xamoterol.
Zafirlukast
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Zafirlukast.
Ziprasidone
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ziprasidone.
Zofenopril
The serum concentration of Methylergometrine can be increased when it is combined with Zofenopril.
Zolmitriptan
Methylergometrine may increase the vasoconstricting activities of Zolmitriptan.
